Integrated network pharmacology and experimental validation to explore the mechanisms of Coregonus peled-derived myosin ACE-inhibiting peptides for the treatment of hypertension.

Coregonus peled is rich in protein and is a plentiful resource of bioactive peptides. This study was aimed at extracting novel Angiotensin I-converting enzyme (ACE) inhibitory peptides from Coregonus peled and revealing their potential hypotensive mechanisms. This paper screened six ACE inhibitory peptides with high bioactivity, good water solubility, and ADMET properties by computerized enzyme digestion of myosin-heavy chain from Coregonus peled , and LCYPR had the greatest ACE inhibition activity (IC 50 = 47.8782 μM). There were 47 potentially critical targets of LCYPR for hypertension treatment, involving 135 biological processes (BP), 30 cellular components (CC), and 30 molecular functions (MF). The results of KEGG pathway analyse showed that the LCYPR participated in 50 pathways including the renin-angiotensin system, renin secretion, lipid and atherosclerosis, relaxin signaling pathway, IL-17 signaling pathway, atherosclerosis, fluid shear stress, and others, through the key targets such as AGT, AKT1, ACE, REN, CTSB, STAT3, PLG, SRC, MMP2, and F2 to regulate the blood pressure of organisms. In conclusion, the study obtained a novel ACE inhibitory peptide from the myosin-heavy chain of Coregonus peled and revealed the potential target and pathway of LCYPR to improve hypertension. The study provides new ideas and methods for developing novel antihypertensive peptides. The results provide a theoretical basis for developing functional foods of the Xinjiang specialty cold-water fish. [ABSTRACT FROM AUTHOR]